From Our 2011 Archives
U.S. Breast Cancer Rates No Longer Declining
Researchers Say an Earlier Decline Due to Reduced Hormone Use Appears to Have Stopped
By Kathleen Doheny
Reviewed by Laura J. Martin, MD
March 1, 2011 -- The decline in U.S. breast cancer rates seen in 2002 and 2003 in white women has not continued, according to a new report that tracks the numbers from 2003 through 2007.
''There was a dramatic decline between 2002 and 2003," says researcher Carol DeSantis, MPH, an epidemiologist with the American Cancer Society and a co-author of the report, conducted with researchers from the National Cancer Institute.
This decline, seen only in white women, was about 7%, she says, and widely attributed to women discontinuing menopausal hormone therapy after results of the large-scale Women's Health Initiative study, released in 2002, found an increased risk of heart disease, stroke, and breast cancer with the use of estrogen-progesterone therapy.
"It appears that the decline from [discontinuing] the use of hormone therapy has stabilized," DeSantis tells WebMD.
Two experts not involved in the study say the findings are not surprising, as they, too, speculate that the effect of discontinuing hormone use by now has stabilized.
The study is published online in Cancer Epidemiology, Biomarkers & Prevention.
Comparing Breast Cancer Rates
DeSantis and colleagues obtained data from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) 12 registries for the years 2000 through 2007.
From 2003 through 2007, DeSantis and her colleagues found the overall breast cancer rates did not change significantly among white women in any age group.
There were no significant changes in breast cancer rates for African-American or Hispanic women from 2003 to 2007 either. Those two groups, however, did not experience the sharp drop found in white women from 2002 to 2003.
When the researchers looked at specific age groups and types of cancer, some rates increased and others decreased from 2003 to 2007. Among the findings:
The researchers say the stabilization in breast cancer rates may also be in part due to the relatively stable rates of screening mammograms in the U.S. since 2000.
Results Not Unexpected
"It's not necessarily that surprising," says Stephanie Bernik, MD, chief of surgical oncology at Lenox Hill Hospital in New York, who reviewed the findings for WebMD.
"Most women stopped taking hormone replacement just for menopausal symptoms," she says. Just 4.2% of white women ages 50-59 took the hormone therapy in 2008, the researchers found.
''With that we expected to see a drop in the rate of breast cancer shortly after that time period," she says. "The thought was it would again stabilize, which I think is what is happening."
Susan Love, MD, president of the Susan Love Research Foundation, agrees there are no surprises."It is likely that the women who were going to stop [hormone therapy] did and that the rates will stabilize at a new lower level as was seen in this study."
She does wonder, however, what is behind the increase in ER-positive cancers and decrease in ER-negative cancers in women in their 40s.
Besides considering the rate of breast cancer, Bernik says, it's important to look at breast cancer survival, which has been increasing. Death rates from breast cancer have been declining since about 1990, according to the American Cancer Society.
On an individual level, women hoping to reduce breast cancer risk can take a number of steps, Bernik says, including getting mammogram screenings regularly, eating well with an emphasis on fruits and vegetables, exercising regularly, not smoking, and limiting alcohol intake.
SOURCES: DeSantis, C. Cancer Epidemiology, Biomarkers & Prevention, published online Feb. 28, 2011.Carol DeSantis, epidemiologist, American Cancer Society, Atlanta.Stephanie Bernik, MD, chief of surgical oncology, Lenox Hill Hospital, New York City.Susan Love, MD, president, Dr. Susan Love Research Foundation, Santa Monica, Calif.
Find support and advances in treatment.